Between baseline and the last study visit, BP control to <140/<90 mm Hg increased from 61.2% to 89.9% (P < .0001). MAP rapidly and significantly improved hypertension control in medically underserved patients, largely as a result of measuring BP accurately and partnering with patients.
accuracy. Even when measured accurately, clinic BP is higher than usual daytime values in about 20% of patients, reflecting an office or white-coat effect. 4 When hypertension is diagnosed and uncontrolled, adequate treatment is the next critical step. Unfortunately, limited confidence in office BP accuracy and concern that office BP may not represent usual daytime values contribute to therapeutic inertia. 5 Therapeutic inertia reflects the failure to initiate or intensify pharmacotherapy when office BP is uncontrolled and can occur in as many as nine of 10 visits in adults with uncontrolled hypertension. 6 Therapeutic inertia contributes to uncontrolled hypertension and may have a greater impact than patient nonadherence with prescribed therapy. 6, 7 Suboptimal adherence with recommended lifestyle changes and antihypertensive medications prescribed to control BP represents the third key barrier to hypertension control. While no single intervention optimizes adherence, 8 a multifactorial approach that includes engaging patients in shared decision-making, 9 patient-centered care, 10 reducing out-of-pocket costs, 11 lowering the pill burden with singlepill combinaitons, 12, 13 consolidating refills, 14 and using reminders 15 can improve adherence.
Minority and uninsured adults often have poorer hypertension control than white and insured adults. 16, 17 Medically underserved adults can experience limited access to health care and difficulties in obtaining and adhering to medications. 17, 18 Our medically underserved 
| METHODS

| Study design and regulatory considerations
Our MAP intervention used a quasi-experimental, prestudy vs poststudy design. The protocol was reviewed by the institutional review board for Greenville Health System. MAP was exempt from written informed consent as the protocol utilized evidence-based processes for managing hypertension. Approval was obtained to use data without protected health information for publication.
The American Medical Association (AMA) partnered with John
Hopkins Medicine to develop the MAP framework: Measure Accurately, Act Rapidly, Partner With Patients, Families, and Communities. 19 Each phase of MAP, designed to address a major barrier to better BP control, included extensive educational materials, audio podcasts, clinical checklists, and teleconferences. MAP was streamlined by the Care Coordination
Institute and AMA to fit the needs of busy primary care practice sites including those with limited resources that serve diverse patient populations.
| Setting
The study was conducted at a single site, the Center for Family Medicine, which serves as a principal location for training residents in
Family Medicine in the Greenville Health System. 
| Study population: inclusion and exclusion criteria
| Unattended AOBP
Patients with an elevated initial BP value were taken to a private examination room. 21 The AOBP protocol was briefly described, the patient was properly positioned, and an appropriate-sized cuff was applied to the upper arm supported at heart level. The staff member then promptly obtained one BP reading to ensure the Omron HEM-907XL was working properly, activated a series of three additional readings at 1-minute intervals without additional rest prior to the first unattended AOBP, and left the room. After the unattended AOBP was completed, the staff member returned and entered the mean of the three unattended AOBP values into the electronic health record with the comment "confirm" to distinguish the unattended AOBP from the attended intake BP.
| Defining key process variables
Measure Accurately was assessed in adults with hypertension as:
Act Rapidly was defined for adults with uncontrolled hypertension by the therapeutic inertia index:
Partner With Patients was defined as the mean of the SBP change for each initiation or intensification of antihypertensive medication in adults with uncontrolled hypertension.
| Monthly feedback reports for physicians and staff
Each staff and resident physician received a monthly "score card" that included BP control for their panel of adults with hypertension, the percentages with an elevated initial BP value that had confirmatory AOBP, their therapeutic inertia score, and the change of SBP with each therapeutic intensification. Patient-level data for each metric were available to physicians.
| Statistical analysis
Descriptive statistics were used to summarize demographic and clini- 
| RESULTS
There 29.3% had one visit, 21.4% had two visits, and 49.3% had three or more visits, ie, more than two thirds (70.7%) had at least two visits. 
| DISCUSSION
Our MAP pilot study demonstrated a clinically and statistically sig- team-based care, perhaps the most effective intervention, during the past 10 to 15 years. 22, 23 BP control attained in this underserved population also approximates control in a large managed care organization with a long-standing hypertension control program. 24 While MAP facilitated team-based care, it did not include additional personnel, eg, nurse clinicians or pharmacists, nutritionists, or community health workers, typically included in team-based interventions. 22, 23 No incremental resources were provided in our streamlined MAP intervention except for automated BP monitors and approximately 2 hours of practice facilitation weekly during the first 3 months, then 2 hours every other week during the last 3 months. The practice facilitator focused on appropriate use of AOBP monitoring (Measure Accurately) when the initial value was high and patient engagement with an emphasis on monthly office visits or other contact in patients with uncontrolled hypertension. In fact, the Measure Accurately and
Partner With Patients components explained most of the BP reduction during our MAP pilot study. Therapeutic inertia was already relatively low at <50% during baseline and did not significantly decline during the intervention. Therapeutic inertia in the current study was much lower than in earlier studies, which concluded that this variable was a greater barrier to hypertension control than patient adherence. 7 The fall in SBP with each therapeutic intensification, a proxy for adherence, increased (Table 3) . When patients with uncontrolled hypertension were selected, the subsequent decline in BP and improvement in control is partially explained by regression to the mean. Regression to the mean is an unlikely explanation for the large rise in hypertension control seen in this clinic population, as this level of change is rarely seen.
The patient population in our MAP pilot study qualified as "medically underserved" based on demographic characteristics and health insurance status. Our clinic serves a large proportion of black adults who are less likely to have controlled hypertension than whites, although the absolute difference was small. Lower hypertension control rates are documented in black and Hispanic than white adults in the United States, especially when assessed in the context of other variables that impact BP control. 16, 25 Of importance, MAP raised BP control similarly in black and white patients (+31.4% vs +29.6%, P = not significant).
It is important to assess our current MAP results in the context of A hypertension quality improvement program was conducted among 14 clinics in Baltimore, Maryland, serving a disproportionately low-income, black population. 26 The factorial study design included The 16-mm Hg mean reduction of SBP among adults with uncontrolled hypertension in our pilot study is similar in magnitude to the reduction seen among the intervention groups in the Baltimore study.
26
A pooled analysis was reported on three cluster randomized trials of health systems-level interventions to improve hypertension control. 27 While the three interventions were not identical, all were F I G U R E 2 Distributions of systolic blood pressure (SBP) and diastolic blood pressure (DBP) for patients with uncontrolled hypertension at baseline and at the last visit during the intervention period (n = 277) designed to improve patient adherence and reduce therapeutic inertia to attain goal BP. The investigators found that initial improvements of hypertension control in blacks were not sustained over the 12-month study. They suggested that future studies should include a run-in period since improvements in hypertension control should be expected at intervention and control sites. Moreover, studies should be powered on small differences in effect size between intervention and control clinics. In our pilot study, the intervention lasted for 6 months. Based on this and other reports, it will be important to assess the sustained effects of our MAP intervention over a year or more.
| STUDY LIMITATIONS
Several limitations of our study should be noted, including the single study site that precludes a randomized control group and the limited duration of the intervention. Hypertension control during the baseline period reflected usual office BP measurements rather than protocol-based BP measurements during the intervention. While not all patients seen during the baseline period had a follow-up visit during the intervention, the majority of eligible patients (78.6%)
were included, lessening the risk of biased sampling. However, patients with both baseline and intervention visits included in the Hispanic ethnicity data were unavailable. Data and counts from categories may not add up to the total because of missing data. a All patients had baseline and at least one follow-up visit during the intervention period, February 2016 to July 2016. b Confirmatory automated office blood pressure (AOBP) data were available in 59 and missing in 27 of the 86 patients with uncontrolled initial blood pressure (BP) at the last intervention visit. *P < .05, **P < .01, ***P < .001.
analysis were more likely to be black and to have diabetes mellitus than patients with only a baseline visit who were excluded. There was no significant change in therapeutic inertia from the baseline period to the intervention period, although baseline therapeutic inertia was already relatively low at <50%. Prior evidence suggests that these lower levels of "clinical inaction" may be appropriate. 28 
| CONCLUSIONS
The preventable toll of hypertension-related cardiovascular and renal diseases is large, especially in medically underserved patients, and the benefits of better hypertension control are well documented. Our pilot study shows that MAP is an effective framework for rapidly improving hypertension control in a resource-limited clinic that serves medically underserved adults. To examine the potential for widespread dissemination, it is important to assess both short-and long-term effects of MAP in a range of clinics that care for diverse populations. Data are presented as mean and standard error or number (percentage). Automated office blood pressure (AOBP) is the mean of three readings with the patient alone in an examination room). Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure; ΔSBP; RxΔ, change in systolic blood pressure after the most recent visit with intensification of antihypertensive medications for uncontrolled hypertension; NA, not available; SBP, systolic blood pressure. *Percentage of visits with uncontrolled blood pressure (BP) with no change in antihypertensive medications.
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